Clinical Trials Logo

Oncology Pain clinical trials

View clinical trials related to Oncology Pain.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05230238 Recruiting - Oncology Pain Clinical Trials

Pituitary Gland Stimulation for Cancer Pain Relief

PGS
Start date: October 12, 2021
Phase: N/A
Study type: Interventional

Patients will undergo an implantation of an extradural pituitary surface electrode in the pituitary fossa. The electrode will be attached to a neurostimulator via which the patient will receive up to 8 (patient requested) stimulations per day.

NCT ID: NCT04931745 Recruiting - Oncology Pain Clinical Trials

Virtual Reality for Port-a-Cath Access

Start date: April 26, 2022
Phase: N/A
Study type: Interventional

Children with cancer almost universally receive port-a-catheters (ports) to deliver medication, fluids, blood products, and conduct blood tests. Port access requires a needle inserted through the skin to the subcutaneous tissue. Despite the application of topical anesthetic, port access can be painful and anxiety producing. Virtual reality (VR) interfaces provide a strategy to reduce anxiety and have been employed in other painful procedures in children. This trial will explore the effectiveness of VR in children undergoing port access.

NCT ID: NCT04737967 Recruiting - Clinical trials for Chemotherapy-induced Peripheral Neuropathy

The Potential Protective Role of Venlafaxine Versus Memantine in Paclitaxel Induced Peripheral Neuropathy

Start date: February 15, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

This is a double blinded two-arm randomized case-only interventional trial. A total of 60 patients who are to receive Paclitaxel to be included and allocated in two groups. The protocol is to be reviewed by the Research Ethics Committee of Faculty of Medicine Cairo University. All procedure will be done in Kasr El-Einy Center of Radiation Oncology and Nuclear Medicine. The first arm (Venlafaxine group) will receive Venlafaxine extended release (37.5 mg) tablets (Zimmerman et al., 2016). The second arm (Memantine group) will receive memantine 10 mg once daily (Morel et al., 2016)